Scancell appoints Dr Cliff Holloway as Chief Executive Officer

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Cliff Holloway as Chief Executive Officer of Scancell, starting 10 January 2018. Cliff will seek to drive progress of Scancell’s immunotherapy platforms ImmunoBody® and Moditope® and oversee their commercialisation. Cliff succeeds Richard Goodfellow who will remain on the Company’s Board of Directors. 

Cliff has over twenty five years’ experience in the life sciences industry. He has held executive management and directorship positions within the biopharmaceutical and diagnostics industry over this period, providing expertise in the development and commercialisation of emerging technologies and drug products, including licensing, M&A, corporate financing, and operations management.

For more information please see the full press release below


More within